Univercells ‘heralds a new era in vaccine production’

By Maggie Lynch contact

- Last updated on GMT

(Image: Getty/scyther5)
(Image: Getty/scyther5)

Related tags: Vaccines, Continuous manufacturing, Continuous processing

After a low cost of manufacturing goal was achieved by a consortium for the development of a bioproduction system for vaccines, Univercells will launch its NevoLine system.

NevoLine, Univercells’ bioproduction system, will be installed at Batavia Biosciences’ polio dedicated facility in Leiden, Netherlands.

NevoLine is an automated bioproduction system designed by Univercells to produce inactivated polio vaccines (sIPV).

The company created it to deliver safer, faster and closed bioprocessing in a smaller footprint by chaining unit steps into a continuous process.

By doing so, users can achieve high yields with less money and time invested. In a statement, Hugues Bultot, CEO and co-founder of Univercells said, “A facility designed with four NevoLine units would deliver up to 50 million sIPV doses per year for an estimated capital cost of $20M.”

The system was initially developed as part of a $12m (€10.5m) Grand Challenges grant from the Bill & Melinda Gates Foundation to deliver affordable sIPV through a consortium of Univercells, Batavia Biosciences, and Merck Millipore.

The sIPV created will cost under $0.30 (£0.23) per trivalent dose. According to Univercells, this cost per dose represents a five-fold reduction in expense, compared to current manufacturing technologies.

From this development, the consortium received a $4m grant extension for the scale-up of the manufacturing system and processes in preparation for clinical and commercial applications.

Per the collaboration, Univercells was responsible for the system while Batavia Biosciences managed the polio manufacturing process, and Merck Millipore supplied the purification membrane.

According to Pierre Morgon, non-executive director and advisor to the CEO, Univercells, the NevoLine system, “heralds a new era in vaccine production,”​ as there is a significant reduction in the amount of upfront capital and manufacturing footprint required for bulk vaccine and biotherapeutics production. He said in a statement that this technology, “will shake the markets to their foundations and enable greater competition by lowering barriers to entry.”

Related news

Show more

Related products

show more

Transforming Clinical Development

Transforming Clinical Development

PerkinElmer | 01-Jun-2021 | Technical / White Paper

The estimated cost of bringing a drug to market in the U.S. according to JAMA is $1 billion.1 The extreme cost of clinical trials urge biopharmaceutical,...

Vaccine Innovation in the Era of COVID19

Vaccine Innovation in the Era of COVID19

Covance Patient Safety | 01-Oct-2020 | Sponsored Link

During this time of worldwide crisis, there is an increasing demand for the acceleration of a vaccination for COVID19. Regardless of the great recent advancements...

Strategies to Achieve Successful Approval & Launch

Strategies to Achieve Successful Approval & Launch

Catalent Pharma Solutions | 03-Sep-2020 | Data Sheet

There are several key considerations to how companies should approach commercial-scale manufacturing that may aid the success of their biologic’s launch...

The Effect of Tamping Force on Bi-Layer Tablets

The Effect of Tamping Force on Bi-Layer Tablets

JRS PHARMA | 15-Aug-2020 | Technical / White Paper

Formulation of bi-layer or multi-layer tablets enables the combination of two or more drugs that may be incompatible or maybe intended for delivery at...

Related suppliers

Follow us

Products

View more

Webinars